(24/7 MARKET NEWS) – Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced, this morning, that the U.S. FDA cleared the company’s Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis (SSc).
Chemomab Therapeutics is at $2.48, up $0.52 (+26.53%), on trading volume of 1.5 million premarket shares.
Its 52-week trading range is $1.75 to $5.5562. It cleared its February resistance levels, but it has a history of quick pops and is a foreign based listing, so probably best to play it for a quick hit.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
